Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix.
Age-distribtuion of HPV
Cervical cancer
Colposcopy
HPV-distribution
HSIL
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
24
11
2020
accepted:
22
01
2021
pubmed:
5
2
2021
medline:
21
10
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
Cervical cancer is caused by persistent infection with high-risk human papillomavirus (hrHPV). Cytology-based national screening programs have reduced the incidence and mortality of cervical cancer. Different hrHPV subtypes have different carcinogenic potentials. This study evaluated the distribution of different types of hrHPV relative to age in cervical cancer and its precursor lesions. HPV testing was performed between November 2018 and February 2020 using the Abbott RealTime high-risk HPV assay on an Abbott m2000sp instrument. This assay separately detects HPV-16, HPV-18, and a pool of 12 additional hrHPV types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68). The study included 652 women with HPV samples and biopsies of the cervix or histology samples obtained during surgery. In all, 30.8% (95% CI, 27.3-34.6%) were HPV-negative. Among HPV-positive women, HPV-16, HPV-18, and "HPV other" types were found in 33.5, 4.4, and 49.4%, respectively. Cervical intraepithelial neoplasia (CIN) 3/high-grade squamous intraepithelial lesions (HSILs) in women ≤ 34 years were positive for HPV-16 in 54.5% of cases and in those ≥ 35 years in 45.4% of cases. Among women with cervical cancer, 75.8% were infected with HPV-16 or had coinfection with HPV-16 and "HPV other". HPV-16 is the most common type of hrHPV in HSIL + lesions. It is more common in women diagnosed with CIN 3/HSIL who are aged ≤ 35 and is decreasing with age. Therefore, women age ≥ 35 with persistent infection with this type of hrHPV need careful surveillance, as they are at high risk of progression to cervical cancer.
Identifiants
pubmed: 33538863
doi: 10.1007/s00404-021-05986-z
pii: 10.1007/s00404-021-05986-z
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-758Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Barnes B et al (2016) RKI Bericht zum Krebsgeschehen in Deutschland 2016. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html
Stuebs FA et al (2019) Accuracy of colposcopy-directed biopsy in detecting early cervical neoplasia: a retrospective study. Arch Gynecol Obstet 299(2):525–532
doi: 10.1007/s00404-018-4953-8
Walboomers JM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19
doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Siegler E et al (2017) Prevalence and genotype distribution of HPV types in women at risk for cervical neoplasia in Israel. Isr Med Assoc J 19(10):635–639
pubmed: 29103242
Friebe K et al (2017) The value of partial HPV genotyping after conization of cervical dysplasias. Geburtshilfe Frauenheilkd 77(8):887–893
doi: 10.1055/s-0043-115395
Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5):342–350
doi: 10.1038/nrc798
International Agency for Research on Cancer Biological agents (2020) Volume 100B: a review of human carcinogens. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B.pdf . Accessed 23 Oct 2020
Bosch FX et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87(11):796–802
doi: 10.1093/jnci/87.11.796
de Sanjose S et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11(11):1048–1056
doi: 10.1016/S1470-2045(10)70230-8
Wang Z et al (2018) Prevalence and distribution of HPV genotypes in 1387 women with cervical intraepithelial neoplasia 2/3 in Shanxi province. China J Cancer 9(16):2802–2806
doi: 10.7150/jca.25614
Baldur-Felskov B et al (2015) Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control 26(8):1105–1116
doi: 10.1007/s10552-015-0603-7
Wang J et al (2017) Effectiveness of cervical screening after age 60 years according to screening history: nationwide cohort study in Sweden. PLoS Med 14(10):e1002414
doi: 10.1371/journal.pmed.1002414
Jentschke M, Hillemanns P (2016) Systematic comparison of different meta-analyses, systematic reviews and HTA reports on cervical cancer screening based on cytology or HPV test. Geburtshilfe Frauenheilkd 76(10):1081–1085
doi: 10.1055/s-0042-112457
Simoes E et al (2013) Cervical cancer screening: defining the need for research. Geburtshilfe Frauenheilkd 73(3):239–246
doi: 10.1055/s-0032-1328303
de Martel C et al (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health 8(2):e180–e190
doi: 10.1016/S2214-109X(19)30488-7
Aro K et al (2019) Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. Gynecol Oncol 154(2):354–359
doi: 10.1016/j.ygyno.2019.05.024
Wheeler CM et al (2009) Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 101(7):475–487
doi: 10.1093/jnci/djn510
Carozzi FM et al (2010) Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 19(9):2389–2400
doi: 10.1158/1055-9965.EPI-10-0131
Lei J et al (2020) HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383(14):1340–1348
doi: 10.1056/NEJMoa1917338
Beckmann MW et al (2014) Establishment of the certification system “gynaecological dysplasia” in Germany. Geburtshilfe Frauenheilkd 74(9):860–867
doi: 10.1055/s-0034-1383042
Bornstein J et al (2012) 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 120(1):166–172
doi: 10.1097/AOG.0b013e318254f90c
Bergman H et al (2019) Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013479
doi: 10.1002/14651858.CD013479
pubmed: 31755549
pmcid: 6873216
Kühn W, Gieseking F (2015) Die aktuellen Empfehlungen der AG-CPC zur Kolposkopie 2015. GYN—Praktische Gynäkologie. https://www.ag-cpc.de/wp-content/uploads/2018/07/Gieseking-Empf-AG-CPC.pdf . Accessed 20 Dec 2020
Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen (2018). https://www.g-ba.de/downloads/39-261-3597/2018-11-22_oKFE-RL_Zervixkarzinom.pdf Accessed 22 Nov 2018
BujanRivera J, Klug SJ (2018) Cervical cancer screening in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61(12):1528–1535
doi: 10.1007/s00103-018-2835-7
Hillemanns P, Mallmann P, Beckmann MW (2016) New screening proposals: the Federal Joint Commission defines the parameters for cervical cancer screening from 2018: statement of the Gynecology Oncology Working Group (AGO). Geburtshilfe Frauenheilkd 76(2):145–146
doi: 10.1055/s-0035-1568209
Hillemanns P et al (2019) Prevention of cervical cancer: guideline of the DGGG and the DKG (S3 Level, AWMF register number 015/027OL, December 2017)—Part 2 on triage, treatment and follow-up. Geburtshilfe Frauenheilkd 79(2):160–176
doi: 10.1055/a-0828-7722
Hillemanns P et al (2019) Prevention of cervical cancer: guideline of the DGGG and the DKG (S3 level, AWMF Register Number 015/027OL, December 2017)—Part 1 with introduction, screening and the pathology of cervical dysplasia. Geburtshilfe Frauenheilkd 79(2):148–159
doi: 10.1055/a-0818-5440
Team, R.C. (2017) A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. https://www.R-project.org/
Brotherton JML et al (2017) Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. Int J Cancer 141(8):1576–1584
doi: 10.1002/ijc.30871
Pretet JL et al (2008) Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 122(2):428–432
doi: 10.1002/ijc.23092
Pretet JL et al (2008) Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 122(2):424–427
doi: 10.1002/ijc.23093
Stuebs FA et al (2020) Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia. Gynecol Oncol 157(2):463–468
doi: 10.1016/j.ygyno.2020.02.026
Leitlinienprogramm Onkologie (2020) (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Prävention des Zervixkarzinoms, Langversion 1.1, AWMF Registernummer: 015/027OL. http://www.leitlinienprogrammonkologie.de/leitlinien/zervixkarzinom-praevention/ abgerufen am 02 Aug 2020